J. Buchi
Président chez AMPIO PHARMACEUTICALS, INC.
Fortune : 2 M $ au 31/05/2024
Profil
J.
Kevin Buchi is currently the Chairman at Ampio Pharmaceuticals, Inc. and the Independent Non-Executive Director at Benitec Biopharma Ltd., Amneal Intermediate, Inc., Benitec Biopharma, Inc., and Amneal Pharmaceuticals, Inc. He previously held positions as the President, Chief Executive Officer & Director at Cephalon, Inc., BioSpecifics Technologies Corp., TetraLogic Pharmaceuticals Corp., and Dicerna Pharmaceuticals, Inc. He also served as the Director at Encysive Pharmaceuticals, Inc., Aptose Biosciences, Inc., Impax Laboratories LLC, Alexza Pharmaceuticals, Inc., Celator Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Arana Therapeutics Ltd., ChemGenex Pharmaceuticals Pty Ltd., Mesoblast Ltd., Alaunos Therapeutics, Inc., Forward Pharma A, Zalicus, Inc., EPIRUS Biopharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.
Mr. Buchi received his undergraduate degree from Cornell University in 1976 and his graduate degree from Kellogg School of Management in 1980.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/05/2024 | 262 072 ( 0,08% ) | 2 M $ | 31/05/2024 | |
BENITEC BIOPHARMA INC
0,56% | 06/12/2023 | 52 097 ( 0,56% ) | 398 542 $ | 31/05/2024 |
| 15/03/2024 | 7 343 ( 0,65% ) | 1 542 $ | 31/05/2024 |
Postes actifs de J. Buchi
| Sociétés | Poste | Début |
|---|---|---|
| BENITEC BIOPHARMA INC. | Directeur/Membre du Conseil | 01/04/2013 |
| AMPIO PHARMACEUTICALS, INC. | Président | 28/05/2022 |
| AMNEAL PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 07/11/2023 |
Amneal Intermediate, Inc.
 Amneal Intermediate, Inc. Pharmaceuticals: MajorHealth Technology Amneal Intermediate, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ. | Directeur/Membre du Conseil | 01/01/2018 |
Benitec Biopharma Ltd.
 Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | Directeur/Membre du Conseil | 11/04/2013 |
Anciens postes connus de J. Buchi
| Sociétés | Poste | Fin |
|---|---|---|
| DICERNA PHARMACEUTICALS, INC. | Président | 28/12/2021 |
| ALAUNOS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 19/05/2021 |
| BIOSPECIFICS TECHNOLOGIES CORP. | Directeur Général | 06/04/2020 |
Impax Laboratories LLC
 Impax Laboratories LLC Pharmaceuticals: MajorHealth Technology Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ. | Directeur Général | 27/03/2017 |
| ░░░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de J. Buchi
| Cornell University | Undergraduate Degree |
| Kellogg School of Management | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 9 |
|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| APTOSE BIOSCIENCES INC. | Health Technology |
| TETRALOGIC PHARMACEUTICALS CORPORATION | Health Technology |
| MESOBLAST LIMITED | Health Technology |
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| AMPIO PHARMACEUTICALS, INC. | Health Technology |
| EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
| BENITEC BIOPHARMA INC. | Health Technology |
| AMNEAL PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 15 |
|---|---|
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
Encysive Pharmaceuticals, Inc.
 Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Health Technology |
BioSpecifics Technologies Corp.
 BioSpecifics Technologies Corp. Pharmaceuticals: MajorHealth Technology BioSpecifics Technologies Corp. engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. It sells its products under the brand XIAFLEX. The company was founded in 1990 and is headquartered in Lynbrook, NY. | Health Technology |
Impax Laboratories LLC
Impax Laboratories LLC Pharmaceuticals: MajorHealth Technology Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ. | Health Technology |
Alexza Pharmaceuticals, Inc.
 Alexza Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexza Pharmaceuticals, Inc. is a pharmaceutical company. It focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are AZ-002 and AZ-007. The company was founded by Alejandro C. Zaffaroni in 2000 and is headquartered in Mountain View, CA. | Health Technology |
Celator Pharmaceuticals, Inc.
 Celator Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Celator Pharmaceuticals, Inc. engages in the research and development of biopharmaceutical products. The company was founded by Lawrence David Mayer, and Marcel B. Bally in 1999 and is headquartered in Ewing, NJ. | Health Technology |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Arana Therapeutics Ltd.
 Arana Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Arana Therapeutics Ltd. engages in researching and developing, investing, licensing, technology, producing, formulating and marketing peptides and related products for the human and animal pharmaceutical industries. It develops and provides human therapeutic products for the treatment of diseases in the areas of cancer and inflammation and products for fertility control in animals. The company was founded in 1985 and is headquartered in Macquarie Park, Australia. | Health Technology |
ChemGenex Pharmaceuticals Pty Ltd.
 ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | Health Technology |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | Health Technology |
Forward Pharma A/S
 Forward Pharma A/S Pharmaceuticals: MajorHealth Technology Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark. | Health Technology |
EPIRUS Biopharmaceuticals, Inc. /Old/
 EPIRUS Biopharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology EPIRUS Biopharmaceuticals, Inc. develops monoclonal antibodies. It offers pharmaceutical products. The company is headquartered in Boston, MA. | Health Technology |
Amneal Intermediate, Inc.
Amneal Intermediate, Inc. Pharmaceuticals: MajorHealth Technology Amneal Intermediate, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
Zalicus, Inc.
 Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
